ABSTRACT
Small cell cervical carcinoma (SCCC) is the most common neuroendocrine tumor in the female genital tract, with an unfavorable prognosis and lacking an evidence-based therapeutic approach. Until now, the distinct subtypes and immune characteristics of SCCC combined with genome and transcriptome have not been described. We performed genomic (n = 18), HPV integration (n = 18), and transcriptomic sequencing (n = 19) of SCCC samples. We assessed differences in immune characteristics between SCCC and conventional cervical cancer, and other small cell neuroendocrine carcinomas, through bioinformatics analysis and immunohistochemical assays. We stratified SCCC patients through non-negative matrix factorization and described the characteristics of these distinct types. We further validated it using multiplex immunofluorescence (n = 77) and investigated its clinical prognostic effect. We confirmed a high frequency of PIK3CA and TP53 alterations and HPV18 integrations in SCCC. SCCC and other small cell carcinoma had similar expression signatures and immune cell infiltration patterns. Comparing patients with SCCC to those with conventional cervical cancer, the former presented immune excluded or 'desert' infiltration. The number of CD8+ cells in the invasion margin of SCCC patients predicted favorable clinical outcomes. We identified three transcriptome subtypes: an inflamed phenotype with high-level expression of genes related to the MHC-II complex (CD74) and IFN-α/ß (SCCC-I), and two neuroendocrine subtypes with high-level expression of ASCL1 or NEUROD1, respectively. Combined with multiple technologies, we found that the neuroendocrine groups had more TP53 mutations and SCCC-I had more PIK3CA mutations. Multiplex immunofluorescence validated these subtypes and SCCC-I was an independent prognostic factor of overall survival. These results provide insights into SCCC tumor heterogeneity and potential therapies. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Subject(s)
Carcinoma, Neuroendocrine , Tumor Microenvironment , Uterine Cervical Neoplasms , Humans , Female , Uterine Cervical Neoplasms/genetics , Uterine Cervical Neoplasms/immunology , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/virology , Tumor Microenvironment/immunology , Tumor Microenvironment/genetics , Carcinoma, Neuroendocrine/genetics , Carcinoma, Neuroendocrine/immunology , Carcinoma, Neuroendocrine/pathology , Carcinoma, Neuroendocrine/mortality , Carcinoma, Small Cell/genetics , Carcinoma, Small Cell/immunology , Carcinoma, Small Cell/pathology , Middle Aged , Biomarkers, Tumor/genetics , Adult , Mutation , Transcriptome , Class I Phosphatidylinositol 3-Kinases/genetics , Prognosis , Gene Expression Profiling/methods , Aged , MultiomicsABSTRACT
Immunotherapies provide effective treatments for previously untreatable tumors and identifying tumor-specific epitopes can help elucidate the molecular determinants of therapy response. Here, we describe a pipeline, ISOTOPE (ISOform-guided prediction of epiTOPEs In Cancer), for the comprehensive identification of tumor-specific splicing-derived epitopes. Using RNA sequencing and mass spectrometry for MHC-I associated proteins, ISOTOPE identified neoepitopes from tumor-specific splicing events that are potentially presented by MHC-I complexes. Analysis of multiple samples indicates that splicing alterations may affect the production of self-epitopes and generate more candidate neoepitopes than somatic mutations. Although there was no difference in the number of splicing-derived neoepitopes between responders and non-responders to immune therapy, higher MHC-I binding affinity was associated with a positive response. Our analyses highlight the diversity of the immunogenic impacts of tumor-specific splicing alterations and the importance of studying splicing alterations to fully characterize tumors in the context of immunotherapies. ISOTOPE is available at https://github.com/comprna/ISOTOPE.
Subject(s)
Epitopes/genetics , Epitopes/immunology , Neoplasms/genetics , Neoplasms/immunology , Alternative Splicing/genetics , Alternative Splicing/immunology , Breast Neoplasms/genetics , Breast Neoplasms/immunology , Carcinoma, Small Cell/genetics , Carcinoma, Small Cell/immunology , Cell Line, Tumor , Computational Biology , Female , Histocompatibility Antigens Class I/genetics , Histocompatibility Antigens Class I/immunology , Humans , Immunotherapy , Lung Neoplasms/genetics , Lung Neoplasms/immunology , Male , Melanoma/genetics , Melanoma/immunology , Models, Genetic , Models, Immunological , Mutation , Neoplasms/therapy , Protein Isoforms/genetics , Protein Isoforms/immunology , RNA Splicing/genetics , RNA Splicing/immunology , RNA-SeqABSTRACT
BACKGROUND: Neoantigen-based personal vaccines and adoptive T cell immunotherapy have shown high efficacy as a cancer treatment in clinical trials. Algorithms for the accurate prediction of neoantigens have played a pivotal role in such studies. Some existing bioinformatics methods, such as MHCflurry and NetMHCpan, identify neoantigens mainly through the prediction of peptide-MHC binding affinity. However, the predictive accuracy of immunogenicity of these methods has been shown to be low. Thus, a ranking algorithm to select highly immunogenic neoantigens of patients is needed urgently in research and clinical practice. RESULTS: We develop TruNeo, an integrated computational pipeline to identify and select highly immunogenic neoantigens based on multiple biological processes. The performance of TruNeo and other algorithms were compared based on data from published literature as well as raw data from a lung cancer patient. Recall rate of immunogenic ones among the top 10-ranked neoantigens were compared based on the published combined data set. Recall rate of TruNeo was 52.63%, which was 2.5 times higher than that predicted by MHCflurry (21.05%), and 2 times higher than NetMHCpan 4 (26.32%). Furthermore, the positive rate of top 10-ranked neoantigens for the lung cancer patient were compared, showing a 50% positive rate identified by TruNeo, which was 2.5 times higher than that predicted by MHCflurry (20%). CONCLUSIONS: TruNeo, which considers multiple biological processes rather than peptide-MHC binding affinity prediction only, provides prioritization of candidate neoantigens with high immunogenicity for neoantigen-targeting personalized immunotherapies.
Subject(s)
Antigens, Neoplasm/metabolism , Precision Medicine , Software , Algorithms , Cancer Vaccines/administration & dosage , Cancer Vaccines/immunology , Carcinoma, Small Cell/immunology , High-Throughput Nucleotide Sequencing , Humans , Lung Neoplasms/immunology , Receptors, Antigen, T-Cell/metabolism , T-Lymphocytes/metabolismABSTRACT
INTRODUCTION: Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune presynaptic neuromuscular disorder. Autoantibodies against subunits of voltage-gated calcium channels (VGCCs) associated with acetylcholine release are thought to cause LEMS. METHODS: HEK293 cells expressing specific individual recombinant subunits of α(1A), α(1B), α(1C), and α(1E); ß(3); and α(2)δ of human neuronal VGCCs were exposed to antibodies from 3 LEMS patients, 1 patient with small-cell lung carcinoma, and 1 with myasthenia gravis. RESULTS: All LEMS patient antibodies bound to cells containing any of the α(1) or ß(3) subunits alone or combined with α(2)δ subunits, but not α(2)δ alone. Autoantibodies from the patient with small-cell lung carcinoma but not the myasthenia gravis patient targeted the same VGCC subunits. CONCLUSIONS: Autoantibodies from LEMS patients bind directly to multiple VGCC α(1) subunits as well as the ß(3) subunit. Thus, multiple components of the presynaptic VGCC complex are prospective targets for antibodies in LEMS.
Subject(s)
Autoantibodies/immunology , Calcium Channels/immunology , Calcium Channels/metabolism , Lambert-Eaton Myasthenic Syndrome/immunology , Protein Subunits/metabolism , Calcium Channels/genetics , Carcinoma, Small Cell/blood , Carcinoma, Small Cell/immunology , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , HEK293 Cells , Humans , Lambert-Eaton Myasthenic Syndrome/blood , Protein Subunits/genetics , TransfectionABSTRACT
Small cell lung cancer (SCLC) accounts for 15 % of all lung tumors and represents an invasive neuroendocrine malignancy with poor survival rates. This cancer is highly prevalent in smokers and characterized by inactivation of p53 and retinoblastoma. First in vitro expansion of circulating tumor cells (CTCs) of SCLC patients allowed for investigation of the cell biology of tumor dissemination. In the suggested CTC SCLC model, the primary tumor attracts and educates tumor-promoting and immunosuppressive macrophages which in turn arm CTCs to spread and generate distal lesions. Preexisting inflammatory processes associated with chronic obstructive pulmonary disease (COPD) seem to potentiate the subsequent activity of tumor-associated macrophages (TAM). Activation of signal transducer and activator of transcription 3 (STAT3) and expression of chitinase-3-like 1/YKL-40 in SCLC CTCs seems to be associated with drug resistance. In conclusion, inflammation-associated generation of invasive and chemoresistant CTCs most likely explains the characteristic features of SCLC, namely early dissemination and rapid failure of chemotherapy.
Subject(s)
Carcinoma, Small Cell/epidemiology , Carcinoma, Small Cell/etiology , Lung Neoplasms/epidemiology , Lung Neoplasms/etiology , Pneumonia/etiology , Smoking/adverse effects , Carcinoma, Small Cell/drug therapy , Carcinoma, Small Cell/immunology , Cross-Sectional Studies , Disease Progression , Drug Resistance, Neoplasm/immunology , Humans , Immune Tolerance/immunology , Lung Neoplasms/drug therapy , Macrophages, Alveolar/immunology , Neoplasm Invasiveness/immunology , Neoplastic Cells, Circulating/immunology , Pneumonia/epidemiology , Pneumonia/immunology , Pulmonary Disease, Chronic Obstructive/epidemiology , Pulmonary Disease, Chronic Obstructive/etiology , Pulmonary Disease, Chronic Obstructive/immunology , Smoking/epidemiology , Smoking/immunologyABSTRACT
CD56+ T cells were studied in samples of peripheral blood from small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) patients compared with healthy controls. Relative numbers of CD56+CD3+ cells were increased in NSCLC (P = 0.001) and SCLC (P = 0.002) compared with normal subjects but their ability to respond to activation by up-regulating CD25 or producing IFN-γ were both significantly impaired. Expression of the killer-immunoglobulin-like receptor CD158a was significantly lower on CD56+CD3+ cells in SCLC than controls and also in early stage compared with late stage NSCLC patients. Mean levels of CD158e were higher in NSCLC patients than controls. CD158e levels on CD56+CD3+ cells were increased in the presence of its ligand HLA-Bw4 compared with controls. Although the precise role of CD56+CD3+ cells is not clear, they appear to be functionally impaired in lung cancer, which may have implications for a reduction of direct or indirect anti-tumour responses.
Subject(s)
CD3 Complex/immunology , CD56 Antigen/immunology , Carcinoma, Non-Small-Cell Lung/immunology , Carcinoma, Small Cell/immunology , Lung Neoplasms/immunology , T-Lymphocyte Subsets/immunology , T-Lymphocytes/immunology , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Small Cell/pathology , Cells, Cultured , HLA-B Antigens/metabolism , Humans , Interferon-gamma/metabolism , Lung Neoplasms/pathology , Lymphocyte Count , Neoplasm Staging , Receptors, KIR2DL1/metabolismABSTRACT
Small cell lung cancer (SCLC) kills at least one person every 2 hr in the United Kingdom. Some patients do relatively well but most have rapidly progressive disease. There is no effective treatment and overall 2-year survival is less than 5%. Patients with SCLC have poorly understood local and systemic immune defects and can be immunocompromised. As CD4(+) T lymphocytes coordinate and regulate immunity, a better understanding of interactions between SCLC tumour cells and CD4(+) T cells may lead to effective molecular immunotherapy. We show that some, but not all, SCLC tumour cell lines secrete molecules that induce IL-10 secretion by and de novo differentiation of functional CD4(+)CD25(+)FOXP3(+)CD127(lo)Helios(-) regulatory T (Treg) cells in healthy blood lymphocytes. FOXP3(+) T cells were found in SCLC tumour biopsies, and patients with higher ratios of FOXP3(+) cells in tumour infiltrates have a worse survival rate. The inhibitory effect of SCLC tumour cells was not affected by blocking IL-10 receptor or TGF-ß signalling but was partially reversed by blocking IL-15, which is reported to be involved in human Treg cells induction. IL-15 was secreted by SCLC cells that inhibited CD4(+) T-cell proliferation and was present in SCLC biopsy tumour cells. These novel findings demonstrate that SCLC tumour cells can induce CD4(+) T-cell-mediated immunosuppression. This gives a potential mechanism by which SCLC tumour cells may downregulate local and systemic immune responses and contribute to poor patient survival. Our data suggest that IL-15 and Treg cells are potential new therapeutic targets to improve immune response and patient survival in SCLC.
Subject(s)
Carcinoma, Small Cell/immunology , Forkhead Transcription Factors/analysis , Lung Neoplasms/immunology , T-Lymphocytes, Regulatory/immunology , Carcinoma, Small Cell/mortality , Carcinoma, Small Cell/pathology , Cell Cycle , Cell Line, Tumor , Humans , Interleukin-10/physiology , Interleukin-15/physiology , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Lymphocyte Activation , Transforming Growth Factor beta/physiologyABSTRACT
BACKGROUND: The CD8 T-cell response to prostate and other cancers is often functionally diminished or absent. This may occur via deletion of tumor-specific T cells, through acquisition of an anergic phenotype, or via active suppression mediated by another population of cells. METHODS: We used a double transgenic model in which mice express CD8 T cells specific for a prostate/prostate cancer antigen to study the response of CD8 T cells to evolving autochronous prostate tumors in TRAMP mice. CD8 T cells were analyzed for functionality by measuring IFN-γ production via flow cytometry and via an in vivo CTL killing assay. In addition, pathological scoring of the prostates of the double transgenic mice was compared to scoring of tumor burden prostates of ProTRAMP mice. RESULTS: Tumor-specific CD8 T cells were not grossly deleted in these animals, but evidenced a clearly non-functional phenotype. Interestingly, full lytic function was rapidly recovered upon removal from tumor-bearing mice. CONCLUSIONS: These data indicate a role for continuous antigen exposure in the maintenance of tumor-specific CD8 T-cell tolerance to prostate cancer.
Subject(s)
CD8-Positive T-Lymphocytes/immunology , Carcinoma, Ductal/immunology , Carcinoma, Small Cell/immunology , Prostatic Intraepithelial Neoplasia/immunology , Prostatic Neoplasms/immunology , Adoptive Transfer , Animals , CD8-Positive T-Lymphocytes/transplantation , Carcinoma, Ductal/pathology , Carcinoma, Small Cell/pathology , Cell Survival , Cell Transplantation , Disease Models, Animal , Female , Interferon-gamma/metabolism , Male , Mice , Mice, Transgenic , Prostatic Intraepithelial Neoplasia/pathology , Prostatic Neoplasms/pathologyABSTRACT
OBJECTIVES: SOX1 antibodies have been described in patients with Lambert-Eaton myasthenic syndrome (LEMS) in association with voltage-gated calcium channel antibodies as serological markers of small cell lung cancer (SCLC). This study was aimed to screen for additional SOX1 autoimmunity in onconeural antibody-positive sera from patients with paraneoplastic neurological syndromes (PNS) other than LEMS and to identify the clinical-immunological profile and associated tumours of patients with coexisting SOX1 antibodies. METHODS: We retrospectively analysed sera from 55 patients with different PNS positive for well-characterized antineuronal antibodies for the presence of SOX1 antibodies by recombinant ELISA and immunoblot. RESULTS: Eight (14.5%) patients showed additional SOX1 antibodies in the ELISA and the recombinant immunoblot. Five patients had coexisting Hu antibodies, while the other three showed coexisting CV2/CRMP5, amphiphysin, and coexisting CV2/CRMP5 and Hu antibodies, respectively. PNS included (partially overlapping) subacute sensory neuropathy, subacute sensorimotor neuropathy, cerebellar degeneration, brainstem encephalitis, encephalomyelitis and limbic encephalitis. No tumour was detected in two patients, while the others had lung cancer (four SCLC and two non-SCLC). One patient showed SOX1-specific intrathecal antibody synthesis. CONCLUSIONS: We describe SOX1 reactivity for the first time overlapping with CV2/CRMP5 and amphiphysin antibodies. SOX1 reactivity is predominantly associated with Hu antibodies and SCLC, but can occur also in other types of lung cancer. Neurological manifestations present in patients with coexisting SOX1 antibodies and well-characterized antineuronal antibodies do not differ from those previously described in patients positive for antineuronal antibodies but no SOX1-specific anti-glial antibodies.
Subject(s)
Autoantibodies/blood , Carcinoma, Small Cell/immunology , Lung Neoplasms/immunology , Paraneoplastic Syndromes, Nervous System/blood , Paraneoplastic Syndromes, Nervous System/immunology , SOXB1 Transcription Factors/immunology , Aged , Carcinoma, Non-Small-Cell Lung/epidemiology , Carcinoma, Non-Small-Cell Lung/immunology , Carcinoma, Small Cell/epidemiology , Female , Humans , Lung Neoplasms/epidemiology , Male , Middle Aged , Paraneoplastic Syndromes, Nervous System/epidemiology , Retrospective Studies , Risk Factors , Seroepidemiologic StudiesABSTRACT
We have found markedly deficient expression of the class I major histocompatibility antigens HLA-A,B,C and beta 2m on human small-cell lung cancer (SCLC) lines and fresh tumor samples. The deficit of HLA-A,B,C and beta 2-microglobulin (beta 2m) antigen expression was demonstrated with both radiobinding assays and indirect immunofluorescence assays. Immunoprecipitation of metabolically labeled cells with antibodies to class I antigens showed most SCLC lines to have synthesized almost no beta 2m and HLA-A,B,C proteins. Northern blot analysis, using human HLA-A,B, and beta 2m cDNA probes, showed that almost all SCLC lines tested had markedly decreased amounts of HLA and beta 2m mRNA, but both gene products could be induced with interferon treatment of SCLC lines. We conclude that human SCLC, in contrast to other lung cancer types, is characterized by greatly reduced transcription of HLA-A,B,C and beta 2m genes, which suggests the existence of a mechanism for evading the host immune response to the tumor and of an E1a-like product in this type of tumor cell.
Subject(s)
Carcinoma, Small Cell/immunology , HLA Antigens/analysis , Lung Neoplasms/immunology , RNA, Messenger/biosynthesis , beta 2-Microglobulin/immunology , Antigens, Surface/analysis , Carcinoma, Small Cell/genetics , Carcinoma, Small Cell/metabolism , Cell Line , Genes, MHC Class II , HLA Antigens/biosynthesis , HLA Antigens/genetics , HLA-A Antigens , HLA-B Antigens , HLA-C Antigens , Humans , Interferons/pharmacology , Lung Neoplasms/genetics , Lung Neoplasms/metabolism , beta 2-Microglobulin/biosynthesis , beta 2-Microglobulin/geneticsABSTRACT
OBJECTIVE: Elevation of serum autoantibodies to alpha-enolase (ENO1) is often seen in inflammation diseases. However, it is unclear whether the levels of serum ENO1 autoantibodies could be affected during tumor progression. Hence, we attempted to determine the relative serum ENO1 autoantibody levels in healthy individuals and various stages of patients with lung and breast cancers. METHODS: Sera were obtained from 99 normal individuals, 21 patients with non-cancer-associated diseases and 178 cancer patients, including Stage I, II and IV non-small cell lung cancer, small cell lung cancer and breast cancer. The ENO1 autoantibody levels were determined by enzyme-linked immunosorbent assay. RESULTS: Compared with the healthy individuals, the levels of ENO1 autoantibodies were significantly decreased in Stage IV non-small cell lung cancer, small cell lung cancer and breast cancer patients. Consistently, this phenomenon was also observed in tumor-grafted mice. Using logistic regression analyses, data show that the titer status of ENO1 autoantibody level is highly associated with the late stage of lung and breast cancers when compared with those of healthy controls. In contrast, there were no statistic differences between healthy controls and early stages of non-small cell lung cancer patients, and total amounts of serum immunoglobulin A, immunoglobulin G and immunoglobulin M levels in Stage IV non-small cell lung cancer patients were not significantly distinct from those of the healthy controls. Thus, the decreased ENO1 autoantibody event in malignant stage of cancer patients is not contributed by reduction in total immunoglobulin. CONCLUSIONS: Marked decrease in the basal level of serum ENO1 autoantibodies is a common malignant event of lung and breast cancers, suggesting that ENO1 autoantibody may serve as a prognostic marker to monitor the disease progression of these cancer patients.
Subject(s)
Autoantibodies/blood , Biomarkers, Tumor/immunology , Breast Neoplasms/immunology , DNA-Binding Proteins/immunology , Lung Neoplasms/immunology , Phosphopyruvate Hydratase/immunology , Tumor Suppressor Proteins/immunology , Adult , Aged , Aged, 80 and over , Animals , Carcinoma, Non-Small-Cell Lung/immunology , Carcinoma, Small Cell/immunology , Down-Regulation , Female , Humans , Male , Mice , Mice, Inbred BALB C , Middle Aged , Young AdultABSTRACT
Although small cell cancer of the lung may have protean manifestations, tumor embolization and inability to identify the primary sites are unusual features. We present a patient with anti-Hu antibody-associated paraneoplastic sensory polyneuropathy and tumor embolism diagnosed by endovascular biopsy to be due to small cell cancer, the primary site of which was not evident. To our knowledge, this patient represents only the second individual to be described with tumor embolization complicating small cell cancer and reminds clinicians of the extended spectrum of this disease.
Subject(s)
Carcinoma, Small Cell/diagnosis , Neoplastic Cells, Circulating/pathology , Paraneoplastic Polyneuropathy/diagnosis , Carcinoma, Small Cell/immunology , ELAV Proteins/blood , Female , Humans , Middle Aged , Paraneoplastic Polyneuropathy/immunologyABSTRACT
Lung cancer remains the leading cause of cancer-related death worldwide. The advent of immune checkpoint inhibitors has led to a paradigm shift in the treatment of metastatic non-small cell and small cell lung cancer. However, despite prolonged overall survival, only a minority of the patients derive clinical benefit from these treatments suggesting that the full anti-tumoral potential of the immune system is not being harnessed yet. One way to overcome this problem is to combine immune checkpoint blockade with different strategies aimed at inducing or restoring cellular immunity in a tumor-specific, robust, and durable way. Owing to their unique capacity to initiate and regulate T cell responses, dendritic cells have been extensively explored as tools for immunotherapy in many tumors, including lung cancer. In this review, we provide an update on the nearly twenty years of experience with dendritic cell-based immunotherapy in lung cancer. We summarize the main results from the early phase trials and give an overview of the future perspectives within this field.
Subject(s)
Dendritic Cells/transplantation , Immunotherapy/methods , Lung Neoplasms/therapy , Antigens, Neoplasm/immunology , Cancer Vaccines/therapeutic use , Carcinoembryonic Antigen/immunology , Carcinoma, Non-Small-Cell Lung/immunology , Carcinoma, Non-Small-Cell Lung/therapy , Carcinoma, Small Cell/immunology , Carcinoma, Small Cell/therapy , Cell Differentiation , Cells, Cultured , Clinical Trials as Topic , Coculture Techniques , Combined Modality Therapy , Cytokine-Induced Killer Cells/immunology , Cytokine-Induced Killer Cells/transplantation , Dendritic Cells/immunology , Humans , Immune Checkpoint Inhibitors/therapeutic use , Immunotherapy, Active , Immunotherapy, Adoptive , Lung Neoplasms/immunology , Monocytes/cytology , Neoplasms/therapy , Treatment OutcomeABSTRACT
Primary esophageal small cell carcinoma (PESCC) is a weakly prevalent but lethal malignancy with early metastasis and a poor prognosis. Currently, neither effective prognostic indicators nor curative therapies are available for PESCC. Immunotherapy has now evolved into one of the most promising therapies for cancer patients. Tumor-infiltrating immune cells which are integral to the tumor immune microenvironment (TIME) are recognized as highly important for prognosis prediction, while the responsiveness to immune checkpoint blockade may be subject to the features of TIME. In this study, we aim to identify the TIME and provide indication for the applicability of immune checkpoint therapy in PESCC. We found that PD-L1 expression was detected in 33.33% (27/81) of all the patients, mostly exhibiting a stroma-only pattern and that it was positively associated with tumor-infiltrating immune cells (CD4+, CD8+, and CD163+). In 74.07% of PD-L1-positive specimens, PD-L1+CD163+ cells were colocalized more with CD4+ than CD8+ T cells. 83.95% (68/81) of all the specimens were infiltrated with more CD4+ than CD8+ T cells. Further analysis showed FoxP3+ Tregs constituted 13-27% of the total CD4+ T cell population. The Kaplan--Meier analysis indicated several factors that contribute to poor survival, including negative PD-L1 expression, rich CD4 expression, rich FoxP3 expression, a low CD8/CD4 ratio, and a high FoxP3/CD8 ratio. A nomogram model was constructed and showed good performance for survival prediction. These results highlight that a suppressive TIME contributes to poor survival of patients with PESCC. TIME analyses might be a promising approach to evaluate the possibility and effect of immune checkpoint-based immunotherapeutics in PESCC patients.
Subject(s)
B7-H1 Antigen/metabolism , Biomarkers, Tumor/metabolism , Carcinoma, Small Cell/mortality , Esophageal Neoplasms/mortality , Lymphocytes, Tumor-Infiltrating/immunology , Tumor-Associated Macrophages/immunology , Adult , Aged , B7-H1 Antigen/analysis , Biomarkers, Tumor/analysis , Carcinoma, Small Cell/immunology , Carcinoma, Small Cell/pathology , Carcinoma, Small Cell/surgery , Esophageal Neoplasms/immunology , Esophageal Neoplasms/pathology , Esophageal Neoplasms/surgery , Esophagectomy , Esophagus/immunology , Esophagus/pathology , Esophagus/surgery , Female , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Nomograms , Tumor Microenvironment/immunologyABSTRACT
We present an illustrative case of a 62-year-old woman with small cell lung cancer who developed progressive worsening of pre-existing anti-Hu antibody associated sensory neuronopathy after treatment with programmed cell death-1 (PD-1) inhibitor, nivolumab. We review the literature and identify 6 reported cases to understand the clinical outcomes of patients with anti-Hu paraneoplastic neurologic syndrome (PNS) treated with anti-PD-1 treatment. The PNS clinical spectrum comprised of encephalitis, a combination of sensory neuronopathy and anti-NMDAR encephalitis, isolated sensory neuronopathy, and encephalomyelitis. Immune checkpoint inhibitor have the potential to worsen pre-existing anti-Hu PNS and may promote the development of anti-Hu PNS.
Subject(s)
Antibodies, Antinuclear/blood , Antineoplastic Agents, Immunological/adverse effects , Autoantigens/immunology , ELAV Proteins/immunology , Nivolumab/adverse effects , Paraneoplastic Syndromes, Nervous System/etiology , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Antibodies, Antinuclear/immunology , Antibodies, Neoplasm , Antineoplastic Agents, Immunological/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carboplatin/administration & dosage , Carcinoma, Small Cell/complications , Carcinoma, Small Cell/drug therapy , Carcinoma, Small Cell/immunology , Carcinoma, Small Cell/secondary , Cerebellar Neoplasms/complications , Cerebellar Neoplasms/drug therapy , Cerebellar Neoplasms/immunology , Cerebellar Neoplasms/secondary , Combined Modality Therapy , Disease Progression , Etoposide/administration & dosage , Female , Humans , Lung Neoplasms/complications , Lung Neoplasms/drug therapy , Lung Neoplasms/immunology , Lung Neoplasms/radiotherapy , Middle Aged , Nivolumab/therapeutic use , Paraneoplastic Syndromes, Nervous System/chemically induced , Paraneoplastic Syndromes, Nervous System/immunology , Radiotherapy, Adjuvant , Treatment OutcomeABSTRACT
HM1.24 antigen (CD317) was originally identified as a cell surface protein that is preferentially overexpressed on multiple myeloma cells. Immunotherapy using anti-HM1.24 antibody has been performed in patients with multiple myeloma as a phase I study. We examined the expression of HM1.24 antigen in lung cancer cells and the possibility of immunotherapy with anti-HM1.24 antibody which can induce antibody-dependent cellular cytotoxicity (ADCC). The expression of HM1.24 antigen in lung cancer cells was examined by flow cytometry as well as immunohistochemistry using anti-HM1.24 antibody. ADCC was evaluated using a 6-h (51)Cr release assay. Effects of various cytokines on the expression of HM1.24 and the ADCC were examined. The antitumor activity of anti-HM1.24 antibody in vivo was examined in SCID mice. HM1.24 antigen was detected in 11 of 26 non-small cell lung cancer cell lines (42%) and four of seven (57%) of small cell lung cancer cells, and also expressed in the tissues of lung cancer. Anti-HM1.24 antibody effectively induced ADCC in HM1.24-positive lung cancer cells. Interferon-beta and -gamma increased the levels of HM1.24 antigen and the susceptibility of lung cancer cells to ADCC. Treatment with anti-HM1.24 antibody inhibited the growth of lung cancer cells expressing HM1.24 antigen in SCID mice. The combined therapy with IFN-beta and anti-HM1.24 antibody showed the enhanced antitumor effects even in the delayed treatment schedule. HM1.24 antigen is a novel immunological target for the treatment of lung cancer with anti-HM1.24 antibody.
Subject(s)
Antibody-Dependent Cell Cytotoxicity/immunology , Antigens, CD/immunology , Immunotherapy , Lung Neoplasms/immunology , Lung Neoplasms/therapy , Membrane Glycoproteins/immunology , Adenocarcinoma/immunology , Adenocarcinoma/metabolism , Adenocarcinoma/therapy , Animals , Antibody-Dependent Cell Cytotoxicity/drug effects , Carcinoma, Large Cell/immunology , Carcinoma, Large Cell/metabolism , Carcinoma, Large Cell/therapy , Carcinoma, Small Cell/immunology , Carcinoma, Small Cell/metabolism , Carcinoma, Small Cell/therapy , Carcinoma, Squamous Cell/immunology , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/therapy , Cell Proliferation , Female , Flow Cytometry , Fluorescent Antibody Technique , GPI-Linked Proteins , Humans , Immunoenzyme Techniques , Lung Neoplasms/metabolism , Membrane Glycoproteins/antagonists & inhibitors , Mice , Mice, SCID , Pleural Effusion, Malignant/immunology , Pleural Effusion, Malignant/metabolism , Pleural Effusion, Malignant/therapy , Tumor Cells, CulturedABSTRACT
A case of brainstem encephalitis in a man positive for both anti-Hu and anti-Ri antibodies is reported. This case had an unusual double step evolution and progressive involvement of different CNS subdivisions at MRI. Brainstem encephalitis developed abruptly, mimicking a posterior vascular deficit with vertigo and dizziness. These symptoms transiently remitted completely after a few days to relapse acutely 1 month later with sudden loss of consciousness, followed by confusion, disorientation, dysarthria, dysphagia and reduced thermic sensation on the right side. Within another few days, the patient developed acute respiratory failure and died some weeks later. MRI was negative at the beginning but later showed a progressive ascending involvement of the brainstem and thalamus. At autopsy, this picture corresponded to lymphocytic infiltration, preferentially B cells into the perivascular spaces and T cells in the brainstem parenchyma, confirming that T cells could be the effector of cytotoxicity, probably in the presence of cooperation with B cells that were well represented in this setting.
Subject(s)
Antibodies, Neoplasm/blood , Autoantibodies/blood , Carcinoma, Small Cell/diagnosis , ELAV Proteins/immunology , Lung Neoplasms/diagnosis , Paraneoplastic Syndromes, Nervous System/diagnosis , Aged , Antibodies, Antinuclear , B-Lymphocytes/immunology , B-Lymphocytes/pathology , Brain Stem/immunology , Brain Stem/pathology , Carcinoma, Small Cell/immunology , Carcinoma, Small Cell/pathology , Diagnosis, Differential , Disease Progression , Hippocampus/immunology , Hippocampus/pathology , Humans , Lung Neoplasms/immunology , Lung Neoplasms/pathology , Magnetic Resonance Imaging , Male , Neurologic Examination , Neurons/immunology , Neurons/pathology , Paraneoplastic Syndromes, Nervous System/immunology , Paraneoplastic Syndromes, Nervous System/pathology , T-Lymphocytes/immunology , T-Lymphocytes/pathology , Thalamus/immunology , Thalamus/pathologyABSTRACT
Four surface antigens previously recognized only in macrophages are present on human small cell lung carcinoma cells and tumors. Cancerous cells may arise from macrophage precursors in bone marrow, and these precursors migrate to lung to participate in the repair of damaged tissue produced by continuous heavy smoking. The characteristic presence of neuropeptides such as bombesin in small cell carcinoma, when considered along with these findings, presents new possibilities for the role of such peptides in nervous, endocrine, and immune system function.
Subject(s)
Antigens, Neoplasm/analysis , Antigens, Surface/analysis , Carcinoma, Small Cell/immunology , Hematopoietic Stem Cells , Lung Neoplasms/immunology , Macrophages/immunology , Carcinoma, Small Cell/etiology , Carcinoma, Small Cell/pathology , Cell Line , Cell Transformation, Neoplastic , Humans , Lung Neoplasms/etiology , Lung Neoplasms/pathology , Monocytes/pathology , SmokingABSTRACT
Lambert-Eaton syndrome, an autoimmune disorder frequently associated with small-cell carcinoma of the lung, is characterized by impaired evoked release of acetylcholine from the motor nerve terminal. Immunoglobulin G (IgG) antibodies from patients with the syndrome, applied to bovine adrenal chromaffin cells, reduced the voltage-dependent calcium channel currents by about 40 percent. When calcium was administered directly into the cytoplasm, however, the IgG-treated cells exhibited normal exocytotic secretion, as assayed by membrane capacitance measurement. Measurement with the fluorescent calcium indicator fura-2 indicated that the IgG treatment reduced potassium-stimulated increase in free intracellular calcium concentration. The pathogenic IgG modified neither kinetics of calcium channel activation nor elementary channel activity, suggesting that a reduction in the number of functional calcium channels underlies the IgG-induced effect. Therefore, Lambert-Eaton syndrome IgG reacts with voltage-dependent calcium channels and blocks their function, a phenomenon that can account for the presynaptic impairment characteristic of this disorder.
Subject(s)
Autoimmune Diseases/immunology , Calcium/metabolism , Immunoglobulin G/physiology , Ion Channels/physiology , Neuromuscular Diseases/immunology , Adrenal Glands/physiopathology , Autoantibodies/physiology , Autoimmune Diseases/physiopathology , Benzofurans , Carcinoma, Small Cell/immunology , Cell Membrane/physiology , Chromaffin System/physiopathology , Electric Conductivity , Exocytosis , Fluorescent Dyes , Fura-2 , Humans , Ion Channels/drug effects , Lung Neoplasms/immunology , Neuromuscular Diseases/physiopathology , Sodium/metabolism , Synapses/immunology , Synapses/physiology , Syndrome , Tetrodotoxin/pharmacologyABSTRACT
A lot of hematologists are often faced with the difficulty of diagnosing bone marrow micrometastasis of carcinoma cells. We employed a new flow cytometric immunophenotyping by a combination of CD45 with three neuroendocrine markers: CD56, microtubule-associated protein-2 and synaptophysin, and successfully detected micrometastatic tumor cells in the bone marrow of a 61-year-old male patient with small cell lung cancer (SCLC), whose marrow smears never showed a distinct morphology of metastasis. It was noteworthy that these SCLC cells accompanied the aberrant expression of CD45, leukocyte common antigen known as a specific marker for hematolymphoid neoplasms, which was not detected in the tumor of primary lesion. We describe this rare case to arouse an attention that tumors of non-hematolymphoid origin can exhibit exceptional CD45-positvity in metastatic sites.